Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Dynavax Technologies Corporation

Healthcare US DVAX

NoneUSD
0.00(0%)

Last update at 2026-03-26T21:08:56.192778Z

Day Range

--
LowHigh

52 Week Range

10.4815.15
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap1505.26M
  • VolumeNone
  • P/E Ratio164.29
  • Dividend Yield-%
  • EBITDA-16.71900M
  • Revenue TTM236.15M
  • Revenue Per Share TTM1.83
  • Gross Profit TTM 448.22M
  • Diluted EPS TTM0.07

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 294.30M 77.52M -75.24000M -152.60000M -158.89900M
Minority interest - - - - -
Net income 293.16M 76.71M -91.77600M -151.39700M -158.89900M
Selling general administrative 131.41M 100.16M 79.26M 74.99M 64.77M
Selling and marketing expenses - - 24.76M - 31.76M
Gross profit 460.53M 265.87M 32.64M 15.83M -13.59800M
Reconciled depreciation 6.67M 7.01M 9.34M 21.53M 14.48M
Ebit 283.52M 134.49M -75.22200M -121.48700M -164.04400M
Ebitda 298.23M 142.28M -67.15300M -114.76700M -149.56100M
Depreciation and amortization 14.71M 7.80M 8.07M 6.72M 14.48M
Non operating income net other 9.82M -53.52400M 4.49M -3.39900M 3.76M
Operating income 283.52M 134.49M -75.22200M -121.48700M -153.31900M
Other operating expenses 440.16M 305.96M 121.77M 156.71M 161.52M
Interest expense 6.73M 11.18M 19.06M 16.98M 9.34M
Tax provision 1.14M 0.81M - - -
Interest income 7.91M 0.14M 1.26M 3.37M 3.83M
Net interest income 1.18M -11.03600M -17.80200M -13.60700M -5.51000M
Extraordinary items - - - - -
Non recurring - - - 13.36M -
Other items - - - - -
Income tax expense 1.14M 0.81M 16.54M -1.20300M 3.76M
Total revenue 722.68M 439.44M 46.55M 35.22M 8.20M
Total operating expenses 178.01M 132.38M 107.86M 137.32M 139.72M
Cost of revenue 262.15M 173.57M 13.91M 19.39M 21.80M
Total other income expense net 10.78M -56.96500M -0.01800M -31.11300M -0.07000M
Discontinued operations - - - - -
Net income from continuing ops 293.16M 76.71M -82.94600M -155.21900M -158.89900M
Net income applicable to common shares 292.87M 81.28M -75.24000M -155.86700M -158.89900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 997.10M 985.85M 1039.25M 353.27M 279.07M
Intangible assets - - - - 2.50M
Earning assets - - - - -
Other current assets 19.00M 85.63M -131.81600M -22.66100M -8.88600M
Total liab 375.02M 404.84M 816.87M 294.58M 270.78M
Total stockholder equity 622.07M 581.01M 222.37M 58.69M 8.29M
Deferred long term liab - - 349.86M - -
Other current liab 0.02M 143.23M 201.36M 32.64M 43.77M
Common stock 0.13M 0.13M 0.12M 0.11M 0.08M
Capital stock 0.13M 0.13M 0.12M 0.11M 0.08M
Retained earnings -930.58400M -924.19500M -1217.35100M -1294.06400M -1218.82400M
Other liab - 0.38M 5.66M 2.57M 1.28M
Good will 2.07M 2.01M 2.12M 2.30M 2.08M
Other assets - 3.52M 0.37M 3.81M 3.56M
Cash 150.28M 202.00M 436.19M 32.07M 39.88M
Cash and equivalents - - - - -
Total current liabilities 62.20M 150.07M 556.40M 77.41M 53.05M
Current deferred revenue 52.43M - 349.86M 38.21M -
Net debt 106.64M 56.01M -178.80600M 185.77M 176.56M
Short term debt 4.50M 3.63M 2.58M 3.25M -
Short long term debt - - - - -
Short long term debt total 256.91M 258.01M 257.38M 217.85M 216.45M
Other stockholder equity 1554.63M 1510.52M 1441.87M 1352.37M 1229.42M
Property plant equipment - 37.60M 60.98M 30.57M 32.02M
Total current assets 859.12M 683.84M 607.28M 228.72M 192.39M
Long term investments - - - - -
Net tangible assets - 579.01M 220.25M 56.40M 3.71M
Short term investments 592.02M 422.39M 109.76M 132.96M 111.17M
Net receivables 44.53M 147.51M 131.82M 22.66M 8.89M
Long term debt 222.70M 221.58M 220.49M 179.81M 178.60M
Inventory 53.29M 59.45M 61.34M 63.69M 41.33M
Accounts payable 5.25M 3.21M 2.60M 3.31M 9.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.10800M -5.43800M -2.26600M 0.27M -2.38700M
Additional paid in capital - - - - -
Common stock total equity - 0.13M 0.12M 0.11M 0.08M
Preferred stock total equity - - - - -
Retained earnings total equity - -924.19500M -1217.35100M -1294.06400M -1218.82400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 74.33M 236.66M 368.85M 65.10M 50.08M
Deferred long term asset charges - - - - -
Non current assets total 137.98M 302.01M 431.96M 124.55M 86.68M
Capital lease obligations 34.22M 36.43M 34.32M 38.04M 37.84M
Long term debt total - 221.58M 220.49M 179.81M 178.60M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -166.65300M -309.85600M 22.70M -22.31100M -13.38100M
Change to liabilities - -373.96100M 310.88M 37.57M -4.52800M
Total cashflows from investing activities - -315.99500M 14.22M -26.53200M -42.78200M
Net borrowings - - 29.63M 29.63M 74.25M
Total cash from financing activities 1.39M 19.52M 55.78M 109.50M 154.35M
Change to operating activities - 98.85M -29.27600M -31.54600M -11.02200M
Net income -6.38900M 293.16M 76.71M -75.24000M -152.60000M
Change in cash -51.65500M -234.19700M 404.10M -7.79000M -9.86700M
Begin period cash flow 202.21M 436.41M 32.31M 40.10M 49.97M
End period cash flow 150.56M 202.21M 436.41M 32.31M 40.10M
Total cash from operating activities 100.56M 62.72M 335.53M -92.25100M -121.25200M
Issuance of capital stock 0.00000M 0.00000M 28.16M 108.54M 79.53M
Depreciation 7.28M 6.67M 7.01M 9.34M 21.53M
Other cashflows from investing activities - 1.00M 1.00M -0.14900M -7.00000M
Dividends paid - - - - -
Change to inventory 3.91M -32.39900M -0.23400M -22.35700M -22.31000M
Change to account receivables 43.27M -15.69900M -138.43100M -45.32100M -17.83600M
Sale purchase of stock - 9.89M 46.81M 109.21M 80.10M
Other cashflows from financing activities -4.97400M 9.89M 217.81M 0.96M 162.65M
Change to netincome - 65.49M 79.58M 6.13M 44.95M
Capital expenditures 4.10M 7.14M 9.48M 11.07M 29.40M
Change receivables - -15.69900M -109.15500M -13.77500M -5.18200M
Cash flows other operating - 126.50M -59.77100M -29.38600M 10.95M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -233.75400M 405.53M -9.28400M -9.68300M
Change in working capital 61.21M -298.41700M 172.22M -32.91400M -33.66600M
Stock based compensation 42.59M 32.91M 21.29M 13.48M 25.46M
Other non cash items 1.12M -33.38100M 1.61M 3.68M 11.97M
Free cash flow 96.46M 55.58M 326.05M -103.32300M -150.65300M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DVAX
Dynavax Technologies Corporation		 - -% - 164.29 400.00 6.67 2.49 4.58 110.08
ZTS
Zoetis Inc		 1.93 2.49% 79.52 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 1.31 4.22% 32.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 14.53 9.74% 163.71 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.34 0.83% 40.58 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Dynavax Technologies Corporation

2100 Powell Street, EmeryVille, CA, United States, 94608

Key Executives

Name Title Year Born
Mr. Ryan Spencer CEO & Director 1978
Mr. David F. Novack Pres & COO 1962
Ms. Kelly MacDonald Sr. VP & CFO 1984
Mr. Michael S. Ostrach Advisor 1952
Dr. Robert Janssen Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs 1954
Mr. Justin Burgess Principal Accounting Officer & Controller NA
Mr. Jeff P. Coon CHRO and Sr. VP of HR & Admin. 1963
Nicole Arndt Sr. Mang. of Investor Relations NA
Mr. John Slebir Sr. VP & Gen. Counsel NA
Ms. Meg Smith VP Sales & Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions